This HTML5 document contains 135 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/chebi/
n25http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/dosage/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/kegg-compound/
n20http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n23http://www.rxlist.com/cgi/generic/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/drugbank/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01327/identifier/national-drug-code-directory/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n26http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01327
rdf:type
n3:Drug
n3:description
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. [PubChem]
n3:dosage
n6:271B3EB5-363D-11E5-9242-09173F13E4C5 n6:271B3EB6-363D-11E5-9242-09173F13E4C5 n6:271B3EB7-363D-11E5-9242-09173F13E4C5 n6:271B3EC1-363D-11E5-9242-09173F13E4C5 n6:271B3EC2-363D-11E5-9242-09173F13E4C5 n6:271B3EAE-363D-11E5-9242-09173F13E4C5 n6:271B3EAF-363D-11E5-9242-09173F13E4C5 n6:271B3EB0-363D-11E5-9242-09173F13E4C5 n6:271B3EB1-363D-11E5-9242-09173F13E4C5 n6:271B3EAA-363D-11E5-9242-09173F13E4C5 n6:271B3EAB-363D-11E5-9242-09173F13E4C5 n6:271B3EAC-363D-11E5-9242-09173F13E4C5 n6:271B3EAD-363D-11E5-9242-09173F13E4C5 n6:271B3EBD-363D-11E5-9242-09173F13E4C5 n6:271B3EBE-363D-11E5-9242-09173F13E4C5 n6:271B3EBF-363D-11E5-9242-09173F13E4C5 n6:271B3EC0-363D-11E5-9242-09173F13E4C5 n6:271B3EB2-363D-11E5-9242-09173F13E4C5 n6:271B3EB3-363D-11E5-9242-09173F13E4C5 n6:271B3EB4-363D-11E5-9242-09173F13E4C5 n6:271B3EBC-363D-11E5-9242-09173F13E4C5 n6:271B3EB8-363D-11E5-9242-09173F13E4C5 n6:271B3EB9-363D-11E5-9242-09173F13E4C5 n6:271B3EBA-363D-11E5-9242-09173F13E4C5 n6:271B3EBB-363D-11E5-9242-09173F13E4C5 n6:271B3EA9-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.
n3:indication
Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.
owl:sameAs
n20:DB01327 n27:DB01327
dcterms:title
Cefazolin
adms:identifier
n11:DB01327 n12:474053 n13:0074-4732-03 n14:PA448839 n17:C06880 n18:D02299 n21:Cefazolin
n3:mechanismOfAction
In vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
n3:packager
n4:271B3E90-363D-11E5-9242-09173F13E4C5 n4:271B3E91-363D-11E5-9242-09173F13E4C5 n4:271B3E8E-363D-11E5-9242-09173F13E4C5 n4:271B3E8F-363D-11E5-9242-09173F13E4C5 n4:271B3E7E-363D-11E5-9242-09173F13E4C5 n4:271B3E84-363D-11E5-9242-09173F13E4C5 n4:271B3E85-363D-11E5-9242-09173F13E4C5 n4:271B3E82-363D-11E5-9242-09173F13E4C5 n4:271B3E83-363D-11E5-9242-09173F13E4C5 n4:271B3E80-363D-11E5-9242-09173F13E4C5 n4:271B3E81-363D-11E5-9242-09173F13E4C5 n4:271B3E7F-363D-11E5-9242-09173F13E4C5 n4:271B3E8C-363D-11E5-9242-09173F13E4C5 n4:271B3E8D-363D-11E5-9242-09173F13E4C5 n4:271B3E8A-363D-11E5-9242-09173F13E4C5 n4:271B3E8B-363D-11E5-9242-09173F13E4C5 n4:271B3E88-363D-11E5-9242-09173F13E4C5 n4:271B3E89-363D-11E5-9242-09173F13E4C5 n4:271B3E86-363D-11E5-9242-09173F13E4C5 n4:271B3E87-363D-11E5-9242-09173F13E4C5 n4:271B3E99-363D-11E5-9242-09173F13E4C5 n4:271B3E9A-363D-11E5-9242-09173F13E4C5 n4:271B3E97-363D-11E5-9242-09173F13E4C5 n4:271B3E98-363D-11E5-9242-09173F13E4C5 n4:271B3E95-363D-11E5-9242-09173F13E4C5 n4:271B3E96-363D-11E5-9242-09173F13E4C5 n4:271B3E93-363D-11E5-9242-09173F13E4C5 n4:271B3E94-363D-11E5-9242-09173F13E4C5 n4:271B3E92-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Cefazolin is present in very low concentrations in the milk of nursing mothers. Cefazolin is excreted unchanged in the urine. In the first six hours approximately 60% of the drug is excreted in the urine and this increases to 70%-80% within 24 hours.
n3:synonym
Cephazoline CEZ Cefazolinum Cefazolina Cephazolin Cephamezine (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Cefazoline Cefamezin Cephazolidin
n24:hasAHFSCode
n25:08-12-06-04
n3:proteinBinding
74-86%
n3:salt
n3:synthesisReference
Michael Bornstein, Sandra M. Carone, "Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration." U.S. Patent US4002748, issued August, 1967.
n8:hasConcept
n9:M0003718
foaf:page
n16:cefazolin.html n23:cefsod.htm
n3:IUPAC-Name
n5:271B3EC7-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B3ECD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B3ECC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B3EC9-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B3ECA-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B3ECB-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B3EC5-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B3EDD-363D-11E5-9242-09173F13E4C5 n5:271B3EC3-363D-11E5-9242-09173F13E4C5 n5:271B3EC6-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B3EC4-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n26:J01DB04
n3:H-Bond-Acceptor-Count
n5:271B3ED3-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B3ED4-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B3ECE-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B3ECF-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B3ED1-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B3ED0-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B3ED2-363D-11E5-9242-09173F13E4C5
n3:absorption
Not absorbed from GI tract. Must be administered parenterally. Peak serum concentrations attained 1-2 hours post intramuscular injection.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
25953-19-9
n3:category
n3:containedIn
n7:271B3EA6-363D-11E5-9242-09173F13E4C5 n7:271B3E9B-363D-11E5-9242-09173F13E4C5 n7:271B3E9C-363D-11E5-9242-09173F13E4C5 n7:271B3EA2-363D-11E5-9242-09173F13E4C5 n7:271B3EA0-363D-11E5-9242-09173F13E4C5 n7:271B3EA1-363D-11E5-9242-09173F13E4C5 n7:271B3E9E-363D-11E5-9242-09173F13E4C5 n7:271B3E9F-363D-11E5-9242-09173F13E4C5 n7:271B3EA7-363D-11E5-9242-09173F13E4C5 n7:271B3EA8-363D-11E5-9242-09173F13E4C5 n7:271B3EA4-363D-11E5-9242-09173F13E4C5 n7:271B3EA5-363D-11E5-9242-09173F13E4C5 n7:271B3EA3-363D-11E5-9242-09173F13E4C5 n7:271B3E9D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B3ED9-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B3EDB-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B3EDC-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B3ED8-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B3ED7-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B3EDA-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B3EC8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B3ED5-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B3ED6-363D-11E5-9242-09173F13E4C5